Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].

Group 1: Company Overview and Strategic Direction - The company is accelerating its production layout in Qujing, Yunnan, leveraging local resources and proximity to Southeast Asia to reduce manufacturing costs and enhance supply chain efficiency [2][3] - The Qujing base is expected to become a key point for expanding into the agricultural market along the Belt and Road Initiative [3] - The local government recognizes the company's strategic direction, leading to collaborations in renewable resources and biopharmaceuticals [3] Group 2: Corporate Governance and Restructuring - Following state-owned capital control, the company established a governance structure with 5 non-independent directors and 2 independent directors, ensuring compliance with state enterprise regulations [4] - The company has implemented a comprehensive evaluation of compliance and management blind spots, alongside a market value management system [4] - The company completed its restructuring process in December 2024, with a new controlling shareholder holding approximately 14.33% of the total shares [3] Group 3: Product Portfolio and Market Position - The company has a strong market presence in various product categories, with market shares for key products such as: - Pyridine: 40%-50% - 2,2'-Bipyridine: 45%-50% - 2,3-Dichloropyridine: 50%-60% [6][7] - The company is the sole producer of certain herbicides, achieving a 100% market share for specific products [7] Group 4: Pricing and Market Trends - The price of Paraquat is stable with a strong order backlog and a 100% operating rate, while the company is increasing exports to India [8] - The company is adapting to market changes, particularly in the herbicide segment, where it is transitioning to more efficient products [8] Group 5: Future Development Strategy and 2025 Plans - The company aims to focus on a synthetic biological industry chain, targeting a 50% global market share in disruptive green products [9][10] - Key projects for 2025 include: - Establishing a 50,000-ton new pyridine cycle economy project in Qujing - Developing a 100,000-ton cassava bioethanol project [10] - The company plans to enhance its market presence through digital marketing and customized green pesticide solutions [10]

Core Viewpoint - The company proposes a cash dividend distribution plan for the fiscal year 2024, with a total distribution amounting to 111,748,483.20 RMB, which represents 42.11% of the net profit attributable to shareholders [3][86]. Company Overview - The company, Hunan Haili Chemical Co., Ltd., operates in the pesticide and chemical industry, which is currently facing challenges such as policy adjustments and changing market demands, leading to a steady decline in total pesticide production in China [6][7]. - Despite these challenges, the overall scale of the pesticide industry remains significant, with increasing market concentration as leading companies accelerate consolidation [6][7]. Financial Performance - For the fiscal year 2024, the company achieved a net profit of 26,540,200 RMB, with total assets amounting to 458,633,360 RMB and equity attributable to shareholders of 315,956,150 RMB as of December 31, 2024 [10][11]. - The company’s total unallocated profits at the end of the fiscal year were 1,225,036,629.08 RMB, and the capital reserve was 1,195,551,098.18 RMB [3][86]. Dividend Distribution Plan - The proposed dividend distribution is set at 2 RMB per 10 shares (including tax), based on a total share capital of 558,742,416 shares as of December 31, 2024 [3][86]. - The plan does not include any capital reserve conversion to increase share capital, and the specific date for the dividend distribution will be announced later [4][87]. Board and Supervisory Committee Decisions - The board of directors and the supervisory committee have approved the annual report, financial settlement report, and the profit distribution plan, which will be submitted for approval at the annual shareholders' meeting [12][63][64]. - The board meeting was held on April 25, 2025, with all members present, ensuring compliance with legal and regulatory requirements [12][56]. Industry Context - The pesticide industry in China is characterized by a fragmented competitive landscape, with major players focusing on research and development to enhance their market positions [6][7]. - The company is also involved in the production of lithium battery materials, which is experiencing growth due to rising demand for electric vehicles [7][9].

Investment Rating - The investment rating for the company is maintained as "Accumulate" with a target price of 12.35 RMB [7][8]. Core Views - The company reported a revenue of 4.64 billion RMB in 2024, a year-on-year decrease of 21%, and a net profit attributable to the parent company of 780 million RMB, down 46% year-on-year. The fourth quarter of 2024 saw a net profit of 200 million RMB, which was an increase of 77% year-on-year and 26% quarter-on-quarter. The company plans to distribute a cash dividend of 0.27 RMB per share for 2024, with a payout ratio of 32% [1][2]. - The agricultural chemical prices are currently in a bottom consolidation phase, and there is an expectation for improvement in market conditions in the future, leading to a maintained "Accumulate" rating [1][4]. Summary by Sections Financial Performance - In 2024, the company's main agricultural chemical revenue was 2.18 billion RMB, down 9% year-on-year, with a sales volume of 85,000 tons, up 37% year-on-year, and an average price of 26,000 RMB per ton, down 34% year-on-year. The overall gross margin decreased by 7.1 percentage points to 30.7% due to market demand issues and increased shipping costs [2][3]. - For Q1 2025, the main agricultural chemical revenue was 480 million RMB, up 8% year-on-year, with an average price increase of 14% to 32,000 RMB per ton. The main agricultural intermediate revenue was 450 million RMB, down 4% year-on-year, with a sales volume increase of 34% to 215,000 tons [3]. Profit Forecast and Valuation - The net profit forecasts for 2025 and 2026 have been adjusted downwards to 860 million RMB and 980 million RMB, respectively, reflecting a decrease of 16% and 27%. The net profit for 2027 is projected to be 1.11 billion RMB, with expected growth rates of 11%, 14%, and 13% for 2025 to 2027 [4][6]. - The estimated EPS for 2025, 2026, and 2027 are 0.95 RMB, 1.08 RMB, and 1.22 RMB, respectively. The company is given a valuation of 13 times PE for 2025, leading to a target price of 12.35 RMB [4][6].

| 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 3288 | -0.2 | -1.8 | -0.09 | | | | | 8 | | | 深证综指 | 1898 | -0.9 | -6.3 | -0.68 | | 风格指数 | 昨日表现 | 1 个月表现 | 6 个月表 | | --- | --- | --- | --- | | | （％） | （％） | 现（％） | | 大盘指数 | -0.06 | -3.09 | -3.93 | | 中盘指数 | -0.6 | -6.26 | -8.52 | | 小盘指数 | -0.85 | -6.2 | -2.74 | | 行业涨幅 | 昨日涨 | 1 个月涨 | 6 个月涨 | | 普钢Ⅱ | 1.64 | -3.29 | 2.87 | | 游戏Ⅱ | 1.3 | -4.5 | 2.38 | | 城商行Ⅱ | 1.24 | 3.41 | 10.11 | | 白色家电 | 1.07 | -3.32 | -4.88 | | 农商 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.6849 | -0.8911 | 23.14 | -0.8576 | | 每股净资产（元） | 0.09 | 0.07 | 28.57 | 0.96 | | 每股公积金(元) | 5.69 | 5.08 | 12.01 | 5.09 | | 每股未分配利润(元) | -6.54 | -5.88 | -11.22 | -4.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 17.93 | 17.42 | 2.93 | 14.45 | | 净利润(亿元) | -2.53 | -3.32 | 23.8 | -3.21 | | 净资产收益率(%) | -237.81 | -173.39 | -37.15 | -55.31 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 10019.62万股 ...

江山股份 20250428 摘要 • 江山股份一季度业绩受益于产品价格和销量双重提升，其中杀虫剂、酰胺 类除草剂、氯碱和日电贸分别贡献毛利占比 30%、18%、13%和 21%， 制剂板块（含杀虫剂、酰胺类除草剂和草甘膦制剂）毛利占比达 20%。 • 公司通过控制销售节奏，将部分产品转入库存以待价格上涨，并在 2025 年一季度适时销售库存产品，推动销量增长。预计二季度酰胺类除草剂销 量将因季节性因素低于一季度。 • 2024 年江山股份制剂板块收入 15 亿元，占总收入约 27%，毛利率为 10.6%，毛利占比 20%，净利润约 4,000 万元。销售费用较高，主要由 于推广费用和人员成本。 • 公司草甘膦目前基本满负荷生产，IDA 法草甘膦开工率约 80%，总体开工 率 80%-90%。库存控制在一个月以内，目前库存量约为半个月产量。 • 草甘膦备货旺季因地区而异，南美洲 9-10 月开始备货，次年 1-2 月进入 用药高峰。价格受气候、生产端事件和政策因素影响，转基因技术推广可 能对草甘膦价格产生影响。 Q&A 请介绍一下江山股份 2025 年第一季度的经营情况。 2025 年第一季度，江山股份实现营业 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1000 | -0.0700 | 242.86 | 0.0600 | | 每股净资产（元） | 9.11 | 8.98 | 1.45 | 9.47 | | 每股公积金(元) | 4.12 | 4.12 | 0 | 3.95 | | 每股未分配利润(元) | 3.37 | 3.44 | -2.03 | 3.94 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.22 | 2.63 | 22.43 | 3.96 | | 净利润(亿元) | 0.16 | -0.11 | 245.45 | 0.1 | | 净资产收益率(%) | 1.03 | -0.70 | 247.14 | 0.64 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 8912.01万股，累计占流通股比： 53.92%，较 ...

Financial Performance - The company reported a basic earnings per share of -0.2300 yuan for 2024, an improvement of 4.17% compared to -0.2400 yuan in 2023 [1] - The total revenue decreased by 12.71% to 10.44 billion yuan in 2024 from 11.96 billion yuan in 2023 [1] - The net profit remained unchanged at -0.39 billion yuan for both 2024 and 2023 [1] - The return on equity was -2.45% in 2024, slightly better than -2.48% in 2023 [1] - The net asset per share decreased marginally to 9.01 yuan in 2024 from 9.03 yuan in 2023, a decline of 0.22% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 87.53 million shares, accounting for 52.97% of the circulating shares, with an increase of 0.8716 million shares compared to the previous period [1] - The largest shareholder, Yin Fengshan, holds 67.7255 million shares, representing 40.98% of the total share capital, with no change in holdings [2] - New entrants among the top shareholders include Xue Qingjie and Bai Rui, holding 1.31 million and 1.28 million shares respectively [2] - UBS AG, Wu Yunfeng, and Wu Hancun have exited the top ten shareholders list [2]

Investment Rating - The report maintains an "Accumulate" investment rating for the company [3] Core Views - The company's Q1 performance met expectations, with revenue of 3.241 billion yuan, a year-on-year increase of 2.04%, and a net profit attributable to shareholders of 435 million yuan, up 1.35% year-on-year [1] - Despite a decline in product sales prices, the company demonstrated strong cost control, and the new Liaoning project is expected to contribute positively to future performance [6] - The agricultural chemicals industry is currently at the bottom of its cycle, but the company is expected to show resilience and potential for profit growth as market conditions improve [6] Financial Data and Valuation - Total revenue projections for the company are as follows: 11.478 billion yuan in 2023, 10.435 billion yuan in 2024, and expected growth to 11.732 billion yuan in 2025, representing a year-on-year growth of 12% [2][9] - The company's net profit is projected to be 1.565 billion yuan in 2023, decreasing to 1.202 billion yuan in 2024, and then increasing to 1.349 billion yuan in 2025, with a corresponding EPS of 3.85 yuan, 2.96 yuan, and 3.32 yuan respectively [2][10] - The current PE ratio is 13.3 for 2023, increasing to 17.3 in 2024, and then decreasing to 15.4 in 2025, indicating a potential undervaluation in the coming years [10] Sales Performance - In Q1 2025, the company's raw material revenue reached 1.81 billion yuan, a year-on-year increase of 4.8%, with sales volume up 14.8% to 28,700 tons, despite a sales price drop of 8.8% [6] - The company's comprehensive gross margin improved by 0.3 percentage points to 24.6% in Q1 2025, reflecting effective cost management [6] Project Development - The company is advancing its innovative pesticide development, with significant progress on the Liaoning project, which is expected to enhance production capabilities and product offerings [6] - The company aims to complete the first phase of the Liaoning project ahead of schedule, with multiple products already yielding qualified outputs [6]